| Identification | |
| Name: | 5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]- |
| Synonyms: | BMS 354825;BMS 35482513;Sprycel;Spyrcel;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; |
| CAS: | 302962-49-8 |
| Molecular Formula: | C22H26ClN7O2S |
| Molecular Weight: | 488.01 |
| InChI: | InChI=1/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2 |
| Molecular Structure: |  |
| Properties | |
| Density: | 1.408g/cm3 |
| Appearance: | pale-yellow solid |
| Usage: | 5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]- (CAS NO.302962-49-8) is used as a new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML and antineoplastic. |
| Safety Data | |
 |
|
